[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Competitor Analysis: IDO & TDO Inhibitors for Modulation of the Tumor Microenvironment

December 2016 | 38 pages | ID: CF7EA6468D8EN
La Merie Publishing

US$ 367.00

Online Subscription

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Competitor Analysis: IDO & TDO Inhibitors for Modulation of the Tumor Microenvironment

This industry report describes the competitive R&D landscape of specific IDO and TDO inhibitors as well as dual target IDO & TDO inhibitors for modulation of the immunosuppressive tumor microenvironment as of December 2016. Selective and dual target novel indoleamine 2,3-dioxygenase (IDO) inhibitors and tryptophan 2,3-dioxygenase (TDO) inhibitors are being evaluated as single agents as well as in combination studies with other immune checkpoint modulators.

Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date as well as the clinical and preclinical combination studies. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in research and development of IDO & TDO inhibitors for modulation of the tumor microenvironment. In addition, the report lists company-specific R&D pipelines of IDO & TDO inhibitors. Competitor projects are listed in a tabular format providing information on:
  • Drug Codes,
  • Target/Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
1) IDO & TDO INHIBITORS

Epacadostat Studies – monotherapy & combinations
Indoximod Studies – monotherapy & combinations
Novel Indoleamine 2,3-Dioxygenase (IDO) Inhibitors
Novel Tryptophan 2,3-Dioxygenase (TDO) Inhibitors
Dual IDO & TDO Inhibitors

2) CORPORATE IDO & TDO INHIBITOR PIPELINES


More Publications